undamentalytics Newsletter

Elevance Health insider trading

Every open-market purchase and sale by Elevance Health's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
Elevance Health insider open-market trades
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Elevance Health’s insiders pay?

From February 8, 2010 to October 23, 2026, 41 insiders reported 9 open-market purchases and 134 sales not made under a pre-set plan in Elevance Health. Twelve months after each purchase was reported, the shares were +11.9% against the S&P 500 on average (median +16.1%), over 6 purchases with a full year of prices; 67% beat the index. After sales, the shares moved +4.3% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 3, 2020 into $31,946 by November 2, 2026, +18.8% a year. It held shares 56% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $17,722 (+8.9% a year), and held throughout $25,669 (+15.0%).

$0$10.0k$20.0k$30.0k 2020202120222023202420252026 $31.9k$25.7k$17.7k
Copying Elevance Health's insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Elevance Health's insiders from February 3, 2020, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 56% of the time.
Elevance Health: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Penczek Ronald W CAO & Controller 0 — — 23 +5.2% (21) June 15, 2026
Hill Julie A Director 0 — — 10 +5.2% (10) May 24, 2021
Zielinski Thomas C EVP & General Counsel 0 — — 10 +8.1% (10) November 4, 2020
Dixon Robert L Jr Director 0 — — 8 −7.1% (7) June 12, 2026
Cannon John EVP, GC & Chief PAO 0 — — 7 +10.3% (7) December 16, 2013
Nussbaum Samuel R Md EVP & Chief Medical Officer 0 — — 7 +12.4% (7) September 15, 2014
Kendrick Charles Morgan Jr EVP & President, Commercial 0 — — 6 −29.8% (5) March 9, 2026
Goulet Kenneth R EVP, Commercial & Specialty 0 — — 5 +1.8% (5) February 20, 2015
Ryan William J Director 0 — — 5 +16.8% (5) July 29, 2016
Brown Randal L EVP & Chief HR Officer 0 — — 4 +14.2% (4) September 6, 2013
Deveydt Wayne S EVP & Chief Financial Officer 0 — — 4 +8.9% (4) August 7, 2014
Jobe Warren Y Director 0 — — 4 +17.1% (4) August 28, 2013
Mccarthy Gloria M EVP & Chief Administrative Off 0 — — 4 +19.6% (4) March 14, 2016
Schaefer George A Jr Director 0 — — 4 +28.2% (4) February 3, 2014
Boudreaux Gail President and CEO 3 +8.7% (2) 50% 0 — July 17, 2026
Burke Sheila P Director 0 — — 3 −17.7% (3) November 7, 2011
Sassi Brian A President & CEO Cons, EVP 1 −26.3% (1) 0% 2 −21.9% (2) August 12, 2011
Baker Lenox D Jr Md Director 0 — — 2 −1.3% (2) March 11, 2013
Bayh Susan B Director 0 — — 2 −13.3% (2) May 23, 2012
Beer Lori A EVP, Specialty Businesses & IT 0 — — 2 +22.6% (2) June 3, 2013
Bush William H T Director 0 — — 2 −17.6% (2) May 9, 2011
Gallina John E SVP & Chief Accounting Officer 0 — — 2 +27.0% (2) June 4, 2014
Kaye Mark EVP & CFO 0 — — 2 −37.7% (1) October 23, 2026
Riegle Donald W Jr Director 0 — — 2 −2.5% (2) September 15, 2010
Schneider Ryan M. Director 2 +35.9% (2) 100% 0 — July 26, 2021
Ward Jackie M Director 0 — — 2 −11.4% (2) February 21, 2012
Collis Steven H Director 1 — — 0 — March 6, 2026
Devore Susan D. Director 1 +8.7% (1) 100% 0 — August 21, 2025
Fluegel Bradley M EVP, Chief Strategy Officer 0 — — 1 +12.1% (1) November 9, 2010
Griffin Brian T EVP & CEO, IngenioRx 0 — — 1 +10.6% (1) May 7, 2018
Haytaian Peter D EVP & President, Commercial 0 — — 1 −7.0% (1) October 30, 2019
Levine Harlan A EVP, CHS 0 — — 1 +30.0% (1) September 5, 2012
Lewis Dijuana K Pres & CEO CHS and EVP 0 — — 1 +28.7% (1) May 24, 2010
Liss Victor S Director 0 — — 1 −5.6% (1) March 12, 2010
Mays William G Director 0 — — 1 −15.6% (1) February 11, 2010
Miller Martin L SVP & Chief Accounting Officer 0 — — 1 +18.0% (1) December 16, 2010
Norwood Felicia F EVP & President,Gov Health Ben 0 — — 1 −31.1% (1) April 25, 2024
Peru Ramiro G Director 1 — — 0 — July 17, 2026
Samitt Craig E EVP & President, DBG 0 — — 1 +9.7% (1) July 27, 2018
Todt Blair Williams EVP, CLO & CAO 0 — — 1 −46.3% (1) December 15, 2023

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). The 40 most active of 41 insiders are shown. A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Elevance Health

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Elevance Health in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −16.0% against the index. After 18 selling crowds, +1.3%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
September 30, 20262 buyingnot yetnot yetnot yet
August 29, 20252 buying+0.5%−16.0%+9.7%
April 30, 20253 selling−46.7%−43.9%−40.9%
April 30, 20243 selling−9.1%−38.5%−35.7%
May 28, 20213 selling−13.7%−5.0%+32.1%
June 30, 20204 selling−9.1%−1.2%+6.2%
December 31, 20193 selling−5.7%−7.9%−12.4%
July 31, 20194 selling−9.6%−20.4%−15.8%
November 30, 20183 selling+0.6%−7.7%−14.8%
September 28, 20183 selling+9.6%+6.3%−14.9%
May 31, 20185 selling+13.0%+30.1%+23.0%
August 31, 20173 selling+12.7%+8.1%+17.3%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Latest 12 of 20. Total returns from the month end; past patterns are not a forecast.

← Back to Elevance Health · Funds · Politicians